Skip to main content

Table 1 Features of the study population

From: Safety, tolerability, and impact on allergic inflammation of autologous E.coli autovaccine in the treatment of house dust mite asthma - a prospective open clinical trial

subject
No.
gender age
[years]
height
[cm]
weight
[kg]
BMI FEV1
[%]
therapy Asthma
severity
1 female 27 161 52 20.1 98.0 BoD <1/w
2 female 27 170 64 22.1 104.0 BoD <1/w
3 female 29 170 70 24.2 94.0 - <1/w
4 female 28 166 54 19.6 109.0 - <1/w
5 male 22 187 85 24.3 127.0 - <1/w
6 male 34 176 80 25.8 118.0 - <1/w
7 female 27 166 59 21.4 82.7 BoD <1/w
8 female 31 180 66 20.4 97.0 - <1/w
9 female 49 163 65 24.4 99.0 BoD <1/w
  1. BoD = betamimetic inhalation on demand; <1/w = less than one exacerbation/week & no limitation of activities